Under the collaboration, the partners will initially focus on optimisation of cystobactamids, a family of natural broad-spectrum myvobacterial topoisomerase inhibitors discovered by HZI researchers that are active against the most Gram-negative pathogens on the WHO priority list. Under the terms of the agreement, Hamburg-based Evotec and German research institute HZI will collaborate for an initial term of three years. The collaboration will combine HZI's unique collection and know-how of natural products as well as access to in vitro and in vivo models of bacterial infection with Evotec's industrial drug discovery platform, expertise in medicinal chemistry and pharmacology as well as huge collection of bacterial pathogens.
Prof. Dirk Heinz, Scientific Director of HZI, said: "Translating insights from infectious diseases research into medical applications as quickly as possible is a crucial part of HZI's mission. Strategic cooperation with clinical and industry partners is vital to delivering on this translational mission by further developing innovative drug candidates such as cystobactamids as a potential tool against dangerous Gram-negative hospital germs. With Evotec we have found a strong and long-term oriented partner whose profile complements HZI's own expertise in antibiotics research extremely well." No financial details of this collaboration were disclosed.
More information: https://european-biotechnology.com/up-to-date/latest-news/news/evotec-and-hzi-join-forces-in-antibiotics-discovery.html